This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ehrchen, J. Articles by Bauer, K. Search for Related Content PubMed PubMed Citation Articles by Ehrchen, J. Articles by Bauer, K. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

Analysis of Thyrotropin-Releasing Hormone-Signaling Components in Pituitary Adenomas of Patients with Acromegaly¹

Max Planck Institut fur Experimentelle Endokrinologie (J.E., A.P., K.B.), D-30625 Hannover, Germany; Neurochirugische Klinik, Universitäts Krankenhaus Eppendorf (D.K.L.), 20246 Hamburg, Germany; and Department of Internal Medicine III and Clinical Endocrinology, Medical Faculty, Erasmus University Rotterdam (T.V.), NL-3000 DR Rotterdam, The Netherlands

Address all correspondence and requests for reprints to: Dr. Karl Bauer, Max Planck Institut fur Experimentelle Endokrinologie, Feodor Lynen Strasse 7, D-30625 Hannover, Germany.

In many acromegalic patients the paradoxical release of GH in response to TRH has been well documented, but the mechanisms underlying this phenomenon are not understood. It has been suggested that aberrant GH secretion may result from TRH endogenously synthesized by the adenoma. In 32 adenomas from acromegalic patients, TRH-like immunoreactivity (TRH-LI) was measured using 2 well characterized antisera. TRH-LI was not detectable in 10 samples, and in 19 samples, TRH-LI was measured only by the less specific antibody. With the TRH-specific antibody, TRH-LI was identified only in 3 samples, 2 of which contained exceedingly high concentrations (40 and 96 pg/mg tissue). In the latter 2 samples, prepro-TRH messenger ribonucleic acid was identified by Northern blot analysis, but not in the control tissue sample of a patient without pituitary disease and also not in the other adenomas analyzed by this technique. Transcripts of the TRH receptor were almost undetectable in all adenomas analyzed. For the TRH-degrading ectoenzyme, a potential regulator of TRH signals at adenohypophyseal target sites, transcripts were significantly expressed only in the TRH-producing adenomas. We conclude that the TRH-signaling elements examined are, in general, not directly involved in the mechanisms causing paradoxical GH secretion in acromegalic patients.